Linktu2021-03-22 04:03
$Glycomimetics(GLYC)$
后期试验:
(1) Uproleselan(GMI-1271):这项正在进行中的关键的3期临床试验(NCT03616470)计划招募380位年龄在18至75岁的复发/难治性急性髓细胞性白血病的患者,这些患者被认为在医学上可以接受强化化疗。
(2) 美国国家癌症研究所的一个财团正在对Uprolese...查看全文
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009744 Size: 5 KB 网页链接
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009743 Size: 7 KB 网页链接
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009745 Size: 4 KB 网页链接
$Glycomimetics(GLYC)$ DEF 14A Other definitive proxy statements Accession Number: 0001558370-24-004448 Act: 34 Size: 1 MB 网页链接
$Glycomimetics(GLYC)$ ARS Annual Report to Security Holders Accession Number: 0001558370-24-004451 Act: 34 Size: 4 MB 网页链接
$Glycomimetics(GLYC)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001558370-24-004078 Act: 33 Size: 178 KB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-24-004015 Act: 34 Size: 427 KB 网页链接
$Glycomimetics(GLYC)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-24-004013 Act: 34 Size: 7 MB 网页链接
$Glycomimetics(GLYC)$ PRE 14A Other preliminary proxy statements Accession Number: 0001558370-24-003788 Act: 34 Size: 1 MB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001558370-24-002241 Act: 34 Size: 7 MB 网页链接